-
1
Association of a COVID-19 diagnosis with adverse events, cohort design, follow-up starting on the day after time 0.
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Arnstein Lindaas (22676409)…”
-
2
Association of a COVID-19 diagnosis with adverse events, SCRI design, marketscan and medicare, follow-up starting on the day after time 0.
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Arnstein Lindaas (22676409)…”
-
3
Eligibility assessment, covariate assessment, and follow-up windows relative to time 0 for the cohort design.
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Arnstein Lindaas (22676409)…”
-
4
Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0.
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Arnstein Lindaas (22676409)…”
-
5
Characteristics of included individuals for SCRI and cohort analyses.
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Arnstein Lindaas (22676409)…”
-
6
Analysis set for each outcome and definition.
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Arnstein Lindaas (22676409)…”
-
7
Eligibility Assessment, Covariate Assessment, Risk Windows, and Reference Windows Relative to Time 0 for the Self-Controlled Risk Interval Design.
Baskı/Yayın Bilgisi 2025Diğer Yazarlar: “…Arnstein Lindaas (22676409)…”